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We are witnessing a pandemic of obesity-related diabetes (1). Dia-
betes predisposes to heart failure, particularly in combination with 
other comorbid conditions such as hypertension and coronary 
artery disease (2, 3). The incidence of heart failure and death fol-
lowing myocardial infarction is higher in diabetic than in nondia-
betic individuals (4–9). Evidence is emerging that derangements in 
cardiac fuel metabolism, related to insulin resistant and diabetic 
states, contribute to the development of diabetic cardiac dysfunc-
tion. The normal adult heart satisfies its energy requirements 
through the oxidation of both fatty acids (FAs) and glucose (10, 11). 
However, myocardial insulin resistance and increased rates of sys-
temic lipolysis force the diabetic heart to rely almost exclusively 
on FA as a fuel source, a loss of substrate flexibility (12–14). Over 
the long term, high rates of myocardial FA utilization predispose 
to the development of a “lipotoxic” form of cardiomyopathy, char-
acterized by myocyte lipid accumulation, mitochondrial dysfunc-
tion, and generation of reactive oxygen species related to excessive 
substrate flux (12–16). In addition, the diabetic heart has a reduced 
capacity for glycolysis and glucose oxidation, which predisposes to 
postischemic damage (17, 18).
Recent evidence has implicated dysregulation of the nuclear 
receptor PPARα (Ppara) in the metabolic and functional derange-
ments of the diabetic heart (19, 20). PPARα activates transcription 
of genes involved in cellular lipid utilization pathways, includ-
ing FA uptake and FA oxidation (FAO) (21, 22). The PPARα gene 
regulatory pathway is chronically activated in the hearts of insu-
lin-deficient and insulin-resistant rodents (19). Transgenic mice 
with cardiac-specific overexpression of PPARα (MHC-PPARα 
mice) display a functional and metabolic phenotype that mimics 
the diabetic heart (19). Specifically, MHC-PPARα mouse hearts 
exhibit increased FAO rates, decreased glucose utilization, myo-
cyte triacylglyceride (TAG) accumulation, and cardiomyopathy. 
Interestingly, the lipotoxic cardiomyopathy of MHC-PPARα mice 
is worsened with consumption of a high-fat (HF) diet (20). Con-
sistent with observations in animal models, recent studies using 
PET have shown that hearts of diabetic humans exhibit increased 
FA uptake and utilization rates (19, 23, 24).
PPARα is a member of a FA-activated nuclear receptor family 
that includes PPARγ (Pparg) and PPARβ/δ (Ppard) (21). In con-
trast to PPARγ, which is adipose enriched, PPARβ/δ is highly 
expressed in cardiac myocytes, similar to PPARα (25). Whereas the 
function of PPARα has been the subject of intense investigation, 
less is known about PPARβ/δ. Mice with cardiac-specific deletion 
of the PPARβ/δ gene were recently shown to develop myocardial 
lipid accumulation and cardiomyopathy (26). These results sug-
gest that PPARβ/δ is necessary for myocardial lipid homeostasis. 
However, the biologic response and corresponding gene activation 
profiles following activation of the PPARβ/δ pathway, compared 
with PPARα, have not been fully delineated.
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To investigate the role of PPARβ/δ in the regulation of heart 
metabolism and function, we generated and characterized trans-
genic mice with cardiac-specific expression of PPARβ/δ (MHC-
PPARβ/δ mice). Surprisingly, in contrast to MHC-PPARα mice, 
MHC-PPARβ/δ mice did not develop cardiomyopathy and exhib-
ited a strikingly different cardiac fuel preference. This PPAR 
isotype–specific response was also observed following ligand-
mediated activation of the endogenous nuclear receptors. The 
PPAR-specific effects on cardiac metabolism were dictated by both 
shared and distinct gene targets. Most notably, PPARβ/δ activated, 
whereas PPARα repressed, targets involved in the cellular glucose 
utilization pathway. Our results suggest that one mechanism 
whereby PPARβ/δ and PPARα exert reciprocal effects on cellular 
glucose uptake occurs through differential regulation of glucose 
transporter 4 (GLUT4; Slc2a4) gene transcription.
Results
Generation of MHC-PPARβ/δ mice. To explore the effects of 
PPARβ/δ in the heart, we generated transgenic mice with car-
diac-specific expression of PPARβ/δ. Three independent lines 
of MHC-PPARβ/δ mice were established, with varying levels of 
transgene expression — from high physiologic to supraphysi-
ologic — compared with endogenous PPARβ/δ; these were des-
ignated low, medium, and high expression (LE, ME, and HE, 
respectively; Figure 1A). The lines of MHC-PPARβ/δ mice were 
chosen so that the range of transgene expression overlapped with 
that of MHC-PPARα lines generated previously; approximately 
20-fold (MHC-PPARβ/δ–LE), 50-fold (MHC-PPARβ/δ–ME), and 
100-fold (MHC-PPARβ/δ–HE) over levels of the correspond-
ing endogenous nuclear receptor (ref. 19 and data not shown). 
MHC-PPARβ/δ transgene expression was confined to the heart 
(data not shown). MHC-PPARβ/δ mice were viable, born in the 
expected Mendelian ratios, and appeared normal.
The expression of known cardiac PPARα target genes was charac-
terized in hearts of MHC-PPARβ/δ mice compared with nontrans-
genic (NTG) littermates. The levels of mRNA encoding muscle 
carnitine palmitoyltransferase Ib (M-CPT 1b; Cpt1b), which cata-
lyzes the rate-limiting step of mitochondrial import of long-chain 
FAs, was induced in MHC-PPARβ/δ–ME and MHC-PPARβ/δ–HE 
mice (Figure 1B). In addition, expression of PPARα target genes 
involved in mitochondrial (medium-, long-, and very long-chain 
acyl-Coenzyme A dehydrogenase [MCAD, Acadm; LCAD, Acadl; 
and VLCAD, Acadvl, respectively]) and peroxisomal (acyl-Coenzyme 
A oxidase [ACO; Acox1]) FAO and FA dethioesterification (mito-
chondrial thioesterase 1 [MTE-1; Mte1]) was significantly higher in 
MHC-PPARβ/δ–ME and MHC-PPARβ/δ–HE mice than in controls 
(Figure 1B). However, only a subset of PPARα target genes (MCAD, 
ACO, and MTE-1) were found to be significantly upregulated in the 
MHC-PPARβ/δ–LE mice (data not shown).
MHC-PPARβ/δ mice do not develop lipotoxic cardiomyopathy. 
MHC-PPARα mice develop cardiac hypertrophy and dysfunc-
tion in association with myocardial lipid accumulation and high 
FA uptake and utilization rates (19), a phenotype that resembles 
the diabetic heart. Hearts from 8-week-old, sex-matched MHC-
PPARα and MHC-PPARβ/δ mice and corresponding NTG lit-
termates were examined for signs of ventricular hypertrophy 
and cardiac dysfunction. As shown previously, the mean biven-
tricular wt/body wt ratio of MHC-PPARα hearts was signifi-
cantly greater than that of controls (3.9 ± 0.2 versus 3.3 ± 0.1; 
P < 0.05), even at low levels of transgene expression. In contrast, 
MHC-PPARβ/δ mice did not exhibit cardiac hypertrophy at any 
level of transgene expression (Supplemental Figure 1A; supple-
mental material available online with this article; doi:10.1172/
JCI32578DS1). Similar results were obtained whether the ven-
tricular weights were normalized to body weight or tibia length 
(Supplemental Figure 1B).
Echocardiography was performed to assess cardiac function of 
MHC-PPARβ/δ mice. On standard chow, LV fractional shortening 
(FS) was modestly but significantly decreased in MHC-PPARα–
LE mice (50.7% ± 5.4%) compared with controls (58.5% ± 6.7%; 
P < 0.05; Figure 2 and Supplemental Table 1). As expected, an 
8-week course of HF diet (43% of total calories as fat) resulted in 
severe cardiac dysfunction in MHC-PPARα–LE mice, manifest as 
a significant decline in LV FS (41.1% ± 5.9%) compared with con-
trols (63.2% ± 5.2%; P < 0.01; Figure 2) as well as systolic and dia-
stolic ventricular dilatation (Supplemental Table 1). In striking 
contrast, MHC-PPARβ/δ–LE mice did not exhibit any evidence 
of ventricular dysfunction or abnormal chamber enlargement 
Figure 1
Generation of MHC-PPARβ/δ mice. (A) Top: Representative autora-
diographs of Northern blot analyses performed with RNA isolated from 
hearts of 8-week-old mice from independent MHC-PPARβ/δ–LE, MHC-
PPARβ/δ–ME, and MHC-PPARβ/δ–HE lines. At the exposure shown, 
endogenous (endo) PPARβ/δ was not detected in NTG samples. Note 
that the endogenous PPARβ/δ transcript was induced in the transgenic 
heart (lower band). The 28s rRNA is shown as a loading control. Bot-
tom: Representative Western blots performed with protein isolated 
from cardiac ventricles of MHC-PPARβ/δ–LE and MHC-PPARβ/δ–HE 
mice. The nonspecific signal is shown as a control for loading. (B) Rep-
resentative Northern blot showing the expression of known PPARα 
target genes in hearts of MHC-PPARβ/δ–ME and MHC-PPARβ/δ–HE 
mice. The 36B4 signal is shown as a loading control.
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on standard or HF diets (Figure 2 and Supplemental Table 1). 
This latter observation held true even in the MHC-PPARβ/δ–HE 
transgenic line (Figure 2).
The absence of a cardiomyopathic phenotype in the MHC-
PPARβ/δ mice led us to explore the metabolic signatures of lipo-
toxicity. MHC-PPARβ/δ and MHC-PPARα mice were fed HF chow 
for 8 weeks or fasted for 48 hours (to rapidly increase circulating 
nonesterified FAs). Levels of myocardial neutral fat were visualized 
semiquantitatively by oil red O staining, followed by characteriza-
tion and quantification of TAG species using electrospray ioniza-
tion mass spectrometry (ESI/MS). In contrast to MHC-PPARα 
mice, MHC-PPARβ/δ hearts did not accumulate abnormal levels 
of neutral lipid (Figure 3A). Similar results were obtained follow-
ing a 48-hour fast (data not shown). Quantification of TAG levels 
by ESI/MS demonstrated a significant increase in myocardial TAG 
levels in MHC-PPARα mice given HF diet or following a 48-hour 
fast compared with controls (Figure 3A). In striking contrast, no 
significant difference in myocardial TAG levels was observed in 
MHC-PPARβ/δ mice compared with controls following HF diet 
or fasting. Taken together with the echocardiographic data, these 
results demonstrate that, in contrast to MHC-PPARα mice, MHC-
PPARβ/δ mice do not develop lipotoxic cardiomyopathy.
Previously, we have shown that neutral lipid accumulation 
within the myocytes of MHC-PPARα hearts is associated with 
activation of target genes involved in cellular FA uptake and TAG 
synthesis. Therefore, we sought to determine whether these gene 
regulatory programs were activated in the MHC-PPARβ/δ mice, 
given the lack of an observed myocardial lipid phenotype. Expres-
sion of genes involved in cellular FA transport was significantly 
upregulated in MHC-PPARα–LE mice, including FA transport 
protein–1 (FATP-1; Slc27a1; 2.42-fold ± 0.09-fold) and CD36 (Cd36) 
(2.13-fold ± 0.09-fold; Figure 3B). In addition, the expression of 
genes encoding several key TAG synthesis and lipogenic enzymes, 
including glycerol-phosphate-3-acyl transferase (GPAT; Gpam), 
acyl-Coenzyme A synthase (ACS; Acsl1), and FA synthase (FAS; 
Fasn), was increased in the hearts of MHC-PPARα mice compared 
with controls (Figure 3B). The expression of the microsomal trans-
fer protein (MTP; Mttp) gene was also markedly increased in the 
MHC-PPARα hearts, presumably as a homeostatic response to 
export excess lipid as lipoprotein. In contrast, expression of the FA 
uptake, lipogenic, and TAG synthesis gene regulatory programs 
was not activated in MHC-PPARβ/δ–HE mouse hearts, with the 
exception of a modest increase in MTP mRNA levels. These results 
suggest that the abnormal TAG accumulation in MHC-PPARα 
mice, but not in MHC-PPARβ/δ mice, is related to differential 
activation of gene regulatory programs involved in FA uptake and 
TAG synthesis in the former, despite activation of genes involved 
in mitochondrial and peroxisomal FAO in both lines (Figure 1B).
MHC-PPARβ/δ mice exhibit increased myocardial glucose uptake and 
utilization rates. The hallmarks of metabolic derangements of the 
diabetic heart include reduced glucose uptake and utilization, con-
comitant with increased FA utilization, a fuel utilization profile 
that is recapitulated in MHC-PPARα mice (19, 27). To assess myo-
cardial fuel utilization in MHC-PPARβ/δ mice, microPET studies 
were performed using 1-11C-glucose and 11C-palmitate as tracers. 
Surprisingly, rates of myocardial glucose uptake were significantly 
increased in MHC-PPARβ/δ–HE mice, whereas 11C-palmitate in 
MHC-PPARβ/δ–HE mice was not different compared with controls 
(Figure 4A). Substrate oxidation rates were determined in working 
hearts isolated from MHC-PPARβ/δ–HE mice and NTG controls 
using [9,10-3H]palmitate and [U-14C]glucose. Consistent with 
the microPET results, glucose oxidation rates were significantly 
increased in MHC-PPARβ/δ–HE hearts (2,155 ± 59 nmol/min/g 
dry wt) compared with controls (1,676 ± 151 nmol/min/g dry wt), 
whereas rates of palmitate oxidation were not significantly differ-
ent (Figure 4B). Consistent with increased reliance on glucose as a 
cardiac substrate, myocardial glycogen levels were higher in MHC-
PPARβ/δ mice than in controls (Figure 4C).
Figure 2
Cardiomyopathy devel-
ops in MHC-PPARα mice, 
but not MHC-PPARβ/δ 
mice. (A) Representa-
tive M-mode echocar-
diographic images of the 
LV of 8-week-old male 
MHC-PPARβ/δ–HE and 
MHC-PPARα–LE mice 
and NTG littermates after 
standard (Std) or HF diet 
treatment. (B) Mean per-
cent LV FS (n ≥ 7 per 
group) as assessed by 
echocardiographic analy-
sis. *P < 0.05 versus NTG; 
**P < 0.05 versus NTG 
and standard diet–treated 
MHC-PPARα–LE.
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PPARβ/δ and PPARα exert differential regulation on genes involved 
in cardiac glucose metabolism. The striking difference in myocardial 
glucose uptake and utilization in MHC-PPARβ/δ compared with 
MHC-PPARα mice prompted us to compare expression of genes 
involved in cardiac glucose metabolism. We previously found that 
the suppressive effects of PPARα on cardiac myocyte glucose utili-
zation occurs at multiple levels including repression of the expres-
sion of genes involved in glucose import (GLUT4) and glycolysis 
(phosphofructokinase [PFK; Pfk]) (19, 20). In contrast, expres-
sion levels of genes encoding GLUT4 and PFK were significantly 
increased in hearts of MHC-PPARβ/δ mice compared with con-
trols (Figure 5A). GLUT1 (Slc2a1) gene expression was increased in 
MHC-PPARα mouse hearts, possibly as a compensatory response 
to the marked downregulation of GLUT4 expression (Figure 5A). 
GLUT1 gene expression was not significantly elevated in MHC-
PPARβ/δ mouse hearts. Levels of hexokinase (HK; Hk2) mRNA 
were not significantly altered in either MHC-PPARα or MHC-
PPARβ/δ mouse hearts (Figure 5A). These results are consistent 
with the substrate uptake and flux data and indicate that PPARβ/δ 
and PPARα exert distinct effects on gene regulatory programs 
involved in cardiac glucose metabolism.
Given that the PPAR isoform–specific gene regulatory patterns 
found in the transgenic lines could reflect an artificial pattern as a 
result of chronic nuclear receptor overexpression, we next assessed 
the effects of activating endogenous PPARα and PPARβ/δ in vivo. 
For these experiments, WT (B6CBAF1/J) mice were treated with 
the PPARα-specific agonist fenofibrate, the PPARβ/δ-specific ago-
nist L-165,041, or vehicle (DMSO) for 3 days. As observed in the 
transgenic mice, treatment with either PPAR agonist resulted in 
increased cardiac expression of MCAD, a known PPAR target gene 
involved in mitochondrial FAO (Figure 5B). In contrast, mice treat-
ed with L-165,041 had increased myocardial GLUT4 and PFK gene 
expression, whereas no increase was observed in mice treated with 
fenofibrate or vehicle (Figure 5B). Rather, fenofibrate treatment 
led to a modest decrease in GLUT4 and PFK mRNA levels. Consis-
tent with the observed difference in myocyte TAG accumulation 
in the transgenic models, cardiac CD36 gene expression (based on 
quantitative RT-PCR analysis) was induced by fenofibrate but not 
by L-165,041 (Figure 5B).
PPAR agonist studies were also performed with rat ventricular car-
diac myocytes in culture to determine whether the observed differen-
tial metabolic and gene regulatory responses were mediated directly 
or via extracardiac effects. Myocytes were treated with fenofibrate, 
L-165,041, or vehicle for 48 hours, followed by analysis of gene 
expression and 2-deoxyglucose (2-DG) uptake rates. Consistent 
with the in vivo findings, basal and insulin-stimulated 2-DG uptake 
rates were increased in cells exposed to L-165,041 (Figure 5C), con-
comitant with increased GLUT4 and PFK gene expression (Supple-
mental Figure 2), whereas no increase was observed in cells treated 
with DMSO or fenofibrate. As also predicted by the in vivo studies, 
both fenofibrate and L-165,041 activated MCAD and M-CPT 1b gene 
expression (Supplemental Figure 2). Collectively, these results dem-
onstrate that PPAR isoform–specific agonists confer the same dif-
ferential pattern of metabolic responses observed in hearts of MHC-
PPARβ/δ and MHC-PPARα mice. Specifically, both PPARβ/δ and 
PPARα activated the FAO pathway, whereas activation of PPARβ/δ, 
but not PPARα, activated the glucose utilization pathway, and 
PPARα, but not PPARβ/δ, activated the FA uptake pathway.
Differential regulation of GLUT4 gene transcription by PPARβ/δ and 
PPARα. As an initial step toward characterizing the mechanism 
involved in the differential regulation of glucose metabolic genes 
by PPARβ/δ and PPARα, transfection studies were performed in 
cardiac ventricular myocytes in culture. For these studies, PPARβ/δ 
or PPARα expression vectors were cotransfected with a reporter 
plasmid containing a firefly luciferase gene driven by 2,240 bp of 
the WT human GLUT4 gene promoter region (GLUT4.Luc.2240; 
Figure 6A) in the presence or absence of PPARα-specific (fenofi-
brate) or PPARβ/δ-specific (L-165,041) ligands. GLUT4.Luc.2240 
Figure 3
Diet-induced myocardial TAG accu-
mulation in MHC-PPARα mice, but 
not MHC-PPARβ/δ mice. (A) Top: 
Histologic appearance of ventricu-
lar tissue samples from male MHC-
PPARα–LE and MHC-PPARβ/δ–HE 
mice and NTG littermates after 4 
weeks of HF diet. Red droplets indi-
cate neutral lipid staining by oil red 
O. Bottom: Myocardial TAG levels 
determined by ESI/MS following HF 
diet or 48-hour fast in male MHC-
PPARα and MHC-PPARβ/δ mice. 
(B) Mean ventricular mRNA levels 
for the indicated genes, as deter-
mined by RT-PCR analysis, shown 
as arbitrary units (AU) normalized to 
the value of NTG controls. RNA was 
isolated from mouse hearts after 4 
weeks of HF diet. The 36B4 signal 
was used as internal normalization 
control. *P < 0.05 versus NTG.
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activity was significantly repressed by PPARα in an exogenous 
ligand–independent manner (Figure 6B). In contrast, PPARβ/δ 
activated GLUT4.Luc.2240, an effect that was additive with 
L-165,041 treatment (Figure 6B). These results, which are consis-
tent with the gene expression studies, demonstrate that PPARα 
and PPARβ/δ exert differential transcriptional regulatory effects 
on the GLUT4 gene. Interestingly, the PPARα-mediated repres-
sive effect was not influenced by addition of exogenous activator, 
whereas the PPARβ/δ-mediated activation was additive with addi-
tion of L-165,041. These latter results suggest that endogenous 
ligand is limiting for PPARβ/δ and/or that the mechanism where-
by PPARα exerts its repressive effect is ligand independent.
We have shown previously that a well-characterized myocyte 
enhancing factor 2a (MEF2a) site within the GLUT4 promoter is 
necessary for the repressive effect of PPARα on GLUT4 transcrip-
tion (28). To determine whether this regulatory site is required for 
the observed differential transcriptional regulation of GLUT4.
Luc.2240 by PPARα and PPARβ/δ, cotransfection studies were 
repeated with a GLUT4 promoter in which the MEF2a site was 
deactivated by site-directed mutagenesis (GLUT4.Luc.MEFM; 
Figure 6A; ref. 28). The PPARα-mediated repressive effect and the 
PPARβ/δ-mediated activation were both abolished with GLUT4.
Luc.MEFM (Figure 6B), demonstrating that the differential tran-
scriptional regulatory effects require the MEF responsive site.
MHC-PPARβ/δ mice are relatively resistant to myocardial ischemia/
reperfusion injury. Previous studies have shown that increased 
rates of myocardial FAO and reduced rates of glucose utilization, 
as occur in the diabetic heart, sensitize the myocardium to isch-
emia/reperfusion (I/R) injury (17, 27, 29, 30). Given that the MHC-
PPARβ/δ mice had increased capacity for myocardial glucose 
uptake and oxidation, we sought to determine whether they were 
resistant to I/R injury. To this end, MHC-PPARβ/δ, MHC-PPARα, 
and WT control mice were subjected to I/R injury by occluding 
the left anterior descending artery for 30 minutes, followed by 24 
hours of reperfusion. Compared with NTG littermates, the hearts 
of MHC-PPARβ/δ mice exhibited significantly less I/R injury, as 
determined by measurement of infarcted area relative to area at risk 
(IA/AAR; 42.8% ± 3.5% versus 59.9% ± 6.8%; P < 0.05; Figure 7). In 
contrast, MHC-PPARα mice had increased IA/AAR compared with 
NTG littermates, although the difference was not statistically sig-
nificant (52.6% ± 4.5% versus 48.3% ± 5.2%; Figure 7). The percent 
area at risk relative to the whole heart was not different between 
NTG and MHC-PPARα mice (42.4% ± 5.6% and 34.9% ± 3.7%) 
or between NTG and MHC-PPARβ/δ mice (49.6% ± 4.8% and 
40.0% ± 3.6%; Supplemental Figure 3). Thus, as predicted by the 
myocardial fuel utilization pattern, MHC-PPARβ/δ mice are rela-
tively protected against I/R injury.
Discussion
The normal postnatal mammalian heart exhibits remarkable fuel 
flexibility, switching between FA and glucose according to nutri-
tional state, physical activity, and diurnal rhythms. This substrate 
Figure 4
Increased myocardial glucose utilization in MHC-PPARβ/δ mice. 
(A) Left: Standardized uptake value time-activity curves for 
11C-palmitate and 11C-glucose into female MHC-PPARβ/δ–HE 
and NTG hearts as determined by microPET. Values are 
mean ± SD. Right: Representative microPET images at 
20 seconds after injection of 11C-palmitate or 11C-glucose. 
Images are normalized to total amount of radioactivity inject-
ed and body weight. The relative amounts of tracer uptake, 
ranging 0–35, are indicated by the color scale. (B) Oxidation 
of [9,10-3H]palmitate and [U-14C]glucose was assessed in iso-
lated working hearts of 12-week-old male MHC-PPARβ/δ–HE 
and NTG control mice. Bars represent mean oxidation 
rates expressed as nanomoles substrate oxidized per gram 
dry mass per minute. (C) Glycogen levels were assessed 
in mouse hearts from male MHC-PPARα–LE and MHC-
PPARβ/δ–HE mice and NTG controls. Results are presented 
as glucose released from glycogen and normalized to tissue 
weight. *P < 0.05 versus NTG.
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flexibility is altered in myocardial disease states. For example, hyper-
tensive heart disease is associated with reduced capacity for cardiac 
FA utilization (31–33). Conversely, the diabetic heart shifts toward 
increased reliance on lipid substrates, leading to excessive rates of 
myocardial FA uptake and oxidation, concomitant with reduced 
glucose utilization. Evidence is emerging that this loss of cardiac 
fuel flexibility contributes to the development of heart failure and 
sensitizes the heart to ischemic injury. The metabolic derangements 
of the diabetic heart involve gene regulatory programming via 
chronic activation of the nuclear receptor PPARα. We have shown 
previously that the cardiac phenotype of MHC-PPARα transgenic 
mice (19) is strikingly similar to the diabetic heart, providing evi-
dence for a link between derangements in myocardial lipid and 
glucose metabolism and cardiac dysfunction. As described herein, 
the related nuclear receptor PPARβ/δ exerted remarkably different 
actions on cardiac metabolism, including versatility in fuel utiliza-
tion associated with preservation of cardiac function.
Myocyte lipid accumulation is characteristic of the diabetic heart 
(34). The term lipotoxicity has been used to describe the toxic effects 
of excessive FA import on cellular function and viability (35). The 
diabetic heart exhibits increased FA uptake and myocyte lipid 
accumulation, ventricular hypertrophy and dysfunction, derange-
ments in mitochondrial function, increased rates of myocyte apop-
tosis, and cardiomyopathy characterized by hypertrophy and dia-
stolic/systolic ventricular dysfunction (36–39). The lipid metabolic 
derangements of the diabetic heart, as modeled by MHC-PPARα 
mice, underscore the impact of chronic PPARα-driven increases in 
myocardial FA uptake and utilization. It is believed that despite 
increased capacity of diabetic and MHC-PPARα hearts to burn fat, 
FAO rates are insufficient to match the high rates of FA import 
and esterification, leading to diversion of FA intermediates to toxic 
pathways including peroxisomal oxidation and ceramide biosyn-
thesis — both of which lead to the generation of cellular toxins (40). 
In this study, we describe the surprising finding that in contrast to 
MHC-PPARα mice, MHC-PPARβ/δ mice did not develop myocyte 
lipid accumulation or cardiomyopathy, even in the context of a 
HF diet. One likely explanation for this striking difference is that 
myocardial FA uptake and esterification rates were increased in 
MHC-PPARα mice but not in MHC-PPARβ/δ mice. The expres-
sion of genes involved in FA uptake (FATP1 and CD36) and tri-
glyceride synthesis (GPAT, ACS, FAS, and MTP) was activated in 
the hearts of MHC-PPARα mice but not in MHC-PPARβ/δ mice. 
This differential gene regulation was also noted when PPARα and 
PPARβ/δ agonists were administered to WT mice. Interestingly, 
genes involved in mitochondrial FAO were activated to similar lev-
els in both transgenes. Collectively, these results suggest that the 
striking differences in cardiac lipid metabolic phenotype exhibited 
by PPARα compared with PPARβ/δ transgenic mice are related to 
differential activation of a subset of gene regulatory programs 
driving cellular transport and esterification of FA.
In 1963, Randle described the glucose-FA cycle (41). This semi-
nal study demonstrated regulatory crosstalk between the 2 major 
fuel utilization pathways in the heart. Specifically, increased flux 
through the FAO pathway generates intermediates that confer 
reciprocal allosteric repressive effects on the pyruvate dehydro-
genase complex, leading to a reduction in glucose oxidation. The 
Figure 5
PPARα- and PPARβ/δ-specific ligands exert differential 
regulation on cardiac metabolic target genes. (A) Mean 
ventricular mRNA levels in MHC-PPARα and MHC-
PPARβ/δ mice, as determined by RT-PCR analysis 
(corrected to 36B4 expression), shown as arbitrary units 
(AU) normalized to the value of NTG controls. (B) Rep-
resentative autoradiographs of Northern blot (left) and 
RT-PCR (right) analyses performed with RNA isolated 
from hearts of WT mice treated with fenofibrate (Feno), 
L-165,041 (L1), or DMSO control for 3 days. (C) Rate 
of 2-DG uptake (mean ± SEM) determined in neonatal 
rat ventricular cardiomyocytes exposed to fenofibrate, 
L-165,041, or DMSO for 48 hours. Rates of 2-DG uptake 
were determined under basal, insulin-stimulated (Ins), or 
cytochalasin B–treated (CytB; to inhibit GLUT4) condi-
tions. *P < 0.05 versus appropriate control.
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repression of glucose oxidation by high rates of FAO described by 
Randle is one likely mechanism whereby myocardial glucose utili-
zation is reduced in the diabetic heart. In addition, the capacity for 
glucose import is constrained in the diabetic heart, which is relat-
ed, at least in part, to decreased insulin-stimulated translocation 
of GLUT4. Evidence is emerging that reduced rates of glucose oxi-
dation contribute to diabetic cardiac dysfunction, particularly in 
the setting of I/R injury (17, 27, 29, 30). Previously we have shown 
that the PPARα-driven increase in myocardial FAO rates in MHC-
PPARα mice is linked to diminished rates of glucose uptake and 
oxidation and reduced expression of the genes encoding GLUT4 
and the glycolytic enzyme PFK (19). This regulatory crosstalk at 
the gene expression level is analogous to the rapid posttranslation-
al control of the Randle cycle. In striking contrast to MHC-PPARα 
mice, MHC-PPARβ/δ mice exhibited increased rates of myocardial 
glucose uptake and utilization. These observations are consistent 
with the results of recent studies by others demonstrating that 
PPARβ/δ promotes insulin sensitivity in muscle and liver (42, 43). 
Our results also demonstrate that, as predicted by the observed 
increased capacity for myocardial glucose utilization, the hearts 
of MHC-PPARβ/δ mice are resistant to I/R injury.
In addition to PPARα and PPARβ/δ, the heart also expresses low 
levels of PPARγ. Recently, the development and characterization of 
mice with cardiac-specific overexpression of PPARγ (MHC-PPARγ) 
have been described previously (44). Similar to MHC-PPARα mice, 
MHC-PPARγ mice have increased expression of CD36, myocyte 
lipid accumulation, increased myocardial uptake, and cardiomy-
opathy (44). This phenotype is similar to that of MHC-PPARα 
mice (19, 20). However, unlike MHC-PPARα mice, myocardial 
GLUT4 mRNA levels and 2-DG uptake are upregulated in the high-
expressing line of MHC-PPARγ mice, a pattern similar to that of 
the MHC-PPARβ/δ mice reported here. Together, these findings 
suggest that PPARγ shares gene regulatory targets and metabolic 
responses in heart with both PPARα and PPARβ/δ. It will be of 
significant interest to delineate shared cardiac PPARα and PPARγ 
gene targets that are distinct from that of PPARβ/δ.
The observation that MHC-PPARβ/δ hearts utilize glucose 
at high rates prompted us to investigate the expression of genes 
involved in this pathway. In contrast to the repressive effects of 
Figure 6
PPARβ/δ and PPARα differentially regulate GLUT4 gene transcrip-
tion through a MEF2a-responsive region in the GLUT4 promoter. 
(A) GLUT4 promoter reporter constructs (GLUT4.Luc.2240 and 
GLUT4.Luc.MEFM) were cotransfected into rat neonatal ventricular 
cardiomyocytes with a PPARα or PPARβ/δ expression vector (pBOS-
PPARα or pCMX-PPARβ/δ) or empty vector control. Cells were 
exposed for 48 hours with fenofibrate, L-165,041, or DMSO control. 
The GLUT4.Luc.MEFM promoter reporter construct is crossed out to 
indicate that the MEF2a binding site has been deactivated by site-
directed mutagenesis. (B) Luciferase activity (mean ± SEM) shown as 
relative luciferase units (RLU) corrected for β-galactosidase activity and 
normalized to the value of empty expression vector–transfected cells 
(n = 12). *P < 0.05 versus empty vector control; **P < 0.01 versus 
DMSO; #P < 0.05 versus DMSO.
Figure 7
MHC-PPARβ/δ mice are resistant to myocardial I/R injury. Top: Rep-
resentative cross-sectional images of the heart after I/R injury followed 
by staining with TTC and Evans blue as described in Methods. Blue 
staining represents uninjured tissue; orange represents area at risk; 
white represents the infarcted region. S, ventricular septum. Bottom: 
IA/AAR (mean ± SEM) for male and female MHC-PPARα–LE and 
MHC-PPARβ/δ–HE mice and corresponding NTG littermates (n ≥ 15 
per group). *P < 0.05 versus NTG.
Downloaded on August 12, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/32578
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 117   Number 12   December 2007 3937
PPARα, we found that PPARβ/δ induced the expression of genes 
encoding GLUT4 (glucose transport) and PFK (glycolysis) in the 
MHC-PPARβ/δ heart. These results do not reflect an artifact of 
overexpression, given that the same patterns were observed in vivo 
and in cultured myocytes using ligand activation of the endog-
enous receptors. To gain further insight into this mechanism, we 
focused on the reciprocal regulation of GLUT4 gene expression 
by PPARα and PPARβ/δ. As predicted by the results of the gene 
expression studies, we found that PPARβ/δ and PPARα exerted 
differential transcriptional regulation of a GLUT4 gene promot-
er-reporter, an effect that requires a well-characterized MEF2a 
response element rather than a PPAR-responsive element. Indeed, 
our analysis of the DNA sequence in the GLUT4 gene 5′-flanking 
region did not reveal a PPAR recognition sequence. Collectively, 
these findings define one mechanism whereby PPAR isotypes exert 
differential regulation on a shared target gene. Future studies 
will be necessary to determine whether this is a general paradigm 
applicable to other differentially regulated targets, including those 
involved in FA uptake and esterification.
Significant evidence supports the notion that therapeutic strate-
gies aimed at reducing myocardial FA uptake and oxidation, while 
increasing glucose utilization, will improve the function of the dia-
betic heart under basal conditions and following ischemic insult. 
We show here that in the setting of myocardial I/R injury, cardiac-
specific overexpression of PPARβ/δ was cardioprotective: infarct 
sizes were smaller in the MHC-PPARβ/δ mice compared with WT 
or MHC-PPARα mice. Interestingly, we have found that expression 
of PPARα, but not PPARβ/δ, is activated in mouse models of type 2 
diabetes, indicating that the ratio of myocardial PPARα to PPARβ/
δ is increased in this disease state (our unpublished observations). 
Accordingly, selective activation of PPARβ/δ shows promise as a 
therapeutic strategy for diabetic cardiac dysfunction if the same 
proves true in humans.
Methods
Materials. The PPARα-specific agonist fenofibrate was obtained from 
Sigma-Aldrich. The PPARβ/δ-specific agonist L-165,041 was obtained 
from Calbiochem.
Generation of MHC-PPARβ/δ mice. A cDNA construct containing a 1.0-kb 
PPARβ/δ cDNA was cloned downstream of the cardiac α-MHC promoter 
(clone 26; gift of J. Robbins, The Children’s Hospital Research Foundation, 
Cincinnati, Ohio, USA). Transgenic mice were generated by microinjection 
of the MHC-PPARβ/δ construct into fertilized 1-cell C57BL/6 × CBA/J F1 
embryos in the Washington University Mouse Genetics Core.
Animal studies. Cardiac functional and metabolic end points were ana-
lyzed in male and female pairs of MHC-PPARβ/δ and littermate NTG mice 
(25–30 g body weight) ranging in age from 8 to 16 weeks. The majority of 
data presented in this manuscript represents studies with male mice, with 
exceptions noted in the figure legends. In each case, independent analyses 
of the opposite gender gave identical results (data not shown). For diet 
studies, mice were allowed ad libitum access to HF chow, which provides 
43% of the calories from fat (TD 97268; Harlan Teklad). For fasting stud-
ies, mice were housed in individual cages at the start of each experiment 
and fasted for 48 hours. Control mice were allowed ad libitum access to 
standard laboratory rodent chow (diet 5053; Purina Mills Inc.). For ago-
nist studies, mice were treated with DMSO, fenofibrate (100 mg/kg/d), 
or L-165,041 (10 mg/kg/d) by oral gavage once daily for 3 days. All animal 
studies were conducted in strict accordance with the NIH guidelines for 
humane treatment of animals and were approved by the Animal Studies 
Committee at Washington University School of Medicine.
Mouse isolated working heart preparation. Mouse working heart perfusions 
were performed as previously described (27). Briefly, isolated working 
hearts were perfused with Krebs-Henseleit solution containing 5 mM 
glucose, 100 μU/ml insulin, and 0.4 mM palmitate. Myocardial FA and 
glucose oxidation rates were determined by quantitative collection of 
3H2O or 14CO2 produced by hearts perfused with buffer containing [9,10-
3H]palmitate or [U-14C]glucose.
Isolated neonatal rat ventricular cardiomyocytes. Neonatal rat ventricular 
cardiomyocytes were isolated as previously described (45); stimulated 
with DMSO, 1 μM fenofibrate, or 10 μM L-165,041 for 48 hours; and 
subjected to RNA isolation for Northern blot analysis or assayed for 
2-DG uptake rates.
2-DG uptake assay. 2-DG uptake rates were determined in isolated neo-
natal rat ventricular cardiomyocytes that were stimulated with DMSO, 
fenofibrate (1 μM), or L-165,041 (10 μM) for 48 hours. Five hours prior 
to the experiment, cells were placed in serum-free medium (Optimem; 
Invitrogen). One hour prior to the experiment, 1 U/ml insulin (Sigma-
Aldrich) and 10 μM cytochalasin B (Sigma-Aldrich) were added to intend-
ed wells. Cells were incubated for 10 minutes with uptake solution (pH 7.4) 
containing [3H]2-DG (2 mCi/ml; American Radiolabeled Nucleotides), 
10 μM 2-DG, 140 mM NaCl, 20 mM HEPES, 5 mM KCl, 2.5 mM MgSO4, 
and 1 mM CaCl2. The reaction was stopped with ice-cold PBS, cells were 
lysed with 50 mM NaOH, lysates were counted by scintillation, and rates 
of 2-DG uptake were calculated.
MicroPET studies. Prior to the imaging session, mice were individually 
housed and semifasted overnight (allowed access to 1 pellet of rodent 
chow). The next morning, mice were fasted for an additional 3 hours 
before experiments were performed. MicroPET imaging of 11C-palmitate 
and 1-11C-glucose uptake and metabolism was performed on the Focus 
120 and 220 (Concord microPET Systems) as previously described (19). 
Briefly, regions of interest were placed on the heart of each mouse using 
the palmitate image as landmark. Regions of interest were normalized 
to animal weight and activity injected to obtain dynamic standardized 
uptake value time activity curves. NTG and MHC-PPARβ/δ dynamic stan-
dardized uptake values were grouped and averaged. MicroPET images 
were similarly standardized.
Echocardiographic studies. Transthoracic M-mode and 2-dimensional echo-
cardiography was performed on conscious mice in the Washington Univer-
sity Mouse Cardiovascular Phenotyping Core using an Acuson Sequoia 256 
Echocardiography system (Acuson Corp.) as described previously (46).
RNA analyses. Total RNA was isolated from mouse cardiac ventricles 
using the RNAzol method (Tel-Test). Northern blot analysis was per-
formed with QuikHyb (Stratagene) using random-primed 32P-labeled 
cDNA clones. Band intensities were quantified using a STORM Phos-
phorimager (GE Healthcare) and normalized to the expression of 36B4 
using ImageQuaNT5.2 software. Real-time quantitative RT-PCR was 
performed using the ABI Prism 7500 Sequence Detection System and 
reagents supplied by Applied Biosystems. Signal intensity was normal-
ized to expression of 36B4.
Immunoblotting studies. Total cardiac protein was prepared as previous-
ly described (47). Western blot analyses were performed using a rabbit 
polyclonal PPARβ/δ (H-74) antibody (Santa Cruz Biotechnology Inc.) and 
a rabbit polyclonal anti-GLUT4 antibody (gift of M. Mueckler, Washington 
University School of Medicine). Detection was performed by measuring the 
chemiluminescent signal as assayed by SuperSignal Ultra (Pierce).
Histologic analyses. Mouse hearts were collected, and a midventricular 
cross-sectional slice of myocardium was immersed in Tissue-Tek OCT 
Compound (Sakura Finetek USA Inc.) and snap-frozen using Cytocool II 
(Richard-Allan Scientific) in a cryomold for sectioning. Sections were 
stained with oil red O to detect intracellular neutral lipid accumulation.
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Myocardial TAG levels. ESI/MS was used to quantitate myocardial TAG 
levels as previously described (48). Briefly, lipids were extracted from mouse 
hearts using a modified Bligh and Dyer technique, and subsequent analysis 
of TAG species was performed in the positive ion mode.
Glycogen measurements. Mouse cardiac tissue from 8-week-old male and 
female MHC-PPARβ/δ and NTG mice was pulverized under liquid nitro-
gen and homogenized in a 0.3 M perchloric acid solution. The muscle 
extract was then assayed with and without amyloglucosidase digestion 
(Sigma-Aldrich) in 50 mM sodium acetate (pH 5.5) and 0.02% BSA. Result-
ing changes in absorption at 340 nM were compared with a standard of 
0–80 μmol glucose. Results are presented as glucose released from glycogen 
and normalized to tissue weight.
Promoter studies. GLUT4 promoter reporter constructs (GLUT4.Luc.2240; 
kindly provided by J. Pessin, University of Iowa, Iowa City, Iowa, USA; and 
GLUT4.Luc.MEFM) were cotransfected into rat neonatal ventricular car-
diomyocytes with a PPARα or PPARβ/δ expression vector (pBos-PPARα or 
pCMX-PPARβ/δ) or empty vector control (pEFBOS or pCMX). Cells were 
stimulated for 48 hours with PPARα-specific (fenofibrate) or PPARβ/δ-
specific (L-164,041) agonists or DMSO control. Luciferase activity in rela-
tive luciferase units was corrected for SV 40 β-galactosidase (500 ng/ml) 
and normalized to the value of empty vector control–transfected cells.
Myocardial I/R studies. Mice were anesthetized (ketamine/xylazine), surgi-
cally prepped and ventilated on a Harvard rodent respirator. After exposing 
the heart, the pericardium was removed, and a 9-0 polypropylene suture 
with a U-shaped needle was passed under the left anterior descending 
artery. The suture was tied over a piece of PE-10 tubing to occlude the left 
anterior descending artery for 30 minutes. After the occlusion period, the 
PE-10 tube was carefully removed to allow for reperfusion. The chest was 
then closed and the mouse recovered. After 24 hours of reperfusion, the 
mouse was again anesthetized and injected subcutaneously with heparin 
(1 U/g). The abdominal cavity was opened, and a heparin/KCL mixture 
was injected into the inferior vena cava to stop the heart. The mouse was 
then bled out by cutting the renal artery. The carotid arteries were ligated, 
the descending aorta was cannulated, and the heart was perfused with a 
phosphate buffer followed by 1% TTC (Fisher). The left anterior descend-
ing artery was then reoccluded at the original site, and 1% Evans Blue Dye 
(Sigma-Aldrich) was perfused. The heart was removed and frozen at –20°C 
for 1 hour, sliced into 5 pieces, and fixed in 4% neutral buffered formalin 
overnight at 4°C. After 24 hours in formalin, the heart slices were weighed. 
An image of each side of all slices was taken using a Canon Power Shot A80 
digital camera. Each image was analyzed using the Image Tool software 
(UTHSCSA). The areas were quantified by averaging both sides of each 
slice and normalizing to slice weight. Next, a region at risk was calculated 
as the portion of the LV absent of blue dye. The percent of infarcted tissue 
(white area) within this region of risk was calculated (see Figure 7).
Statistics. Data were analyzed by 2-tailed Student’s t test or ANOVA and 
presented as mean ± SEM. A P value less than 0.05 was considered statisti-
cally significant.
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